Ayala Pharmaceuticals (ADXS) Competitors

$0.60 0.00 (0.00%)

As of 05/18/2026

ADXS vs. DERM, RANI, AARD, GNLX, and IPHA

Should you buy Ayala Pharmaceuticals stock or one of its competitors? MarketBeat compares Ayala Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ayala Pharmaceuticals include Journey Medical (DERM), Rani Therapeutics (RANI), Aardvark Therapeutics (AARD), Genelux (GNLX), and Innate Pharma (IPHA). These companies are all part of the "pharmaceutical products" industry.

How does Ayala Pharmaceuticals compare to Journey Medical?

Ayala Pharmaceuticals (NASDAQ:ADXS) and Journey Medical (NASDAQ:DERM) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, dividends, profitability and institutional ownership.

Ayala Pharmaceuticals has a net margin of 0.00% compared to Journey Medical's net margin of -14.82%. Ayala Pharmaceuticals' return on equity of 0.00% beat Journey Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ayala Pharmaceuticals	N/A	N/A	N/A
Journey Medical	-14.82%	-35.57%	-10.88%

7.2% of Ayala Pharmaceuticals shares are held by institutional investors. Comparatively, 7.3% of Journey Medical shares are held by institutional investors. 0.6% of Ayala Pharmaceuticals shares are held by insiders. Comparatively, 15.0% of Journey Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Journey Medical had 19 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 20 mentions for Journey Medical and 1 mentions for Ayala Pharmaceuticals. Ayala Pharmaceuticals' average media sentiment score of 0.00 beat Journey Medical's score of -0.51 indicating that Ayala Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ayala Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Journey Medical	1 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Ayala Pharmaceuticals has a beta of 1.75, suggesting that its share price is 75% more volatile than the broader market. Comparatively, Journey Medical has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market.

Journey Medical has a consensus price target of $13.00, indicating a potential upside of 111.38%. Given Journey Medical's stronger consensus rating and higher probable upside, analysts clearly believe Journey Medical is more favorable than Ayala Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Journey Medical has higher revenue and earnings than Ayala Pharmaceuticals. Journey Medical is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A
Journey Medical	$61.86M	2.72	-$11.43M	-$0.37	N/A

Summary

Journey Medical beats Ayala Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Ayala Pharmaceuticals compare to Rani Therapeutics?

Ayala Pharmaceuticals (NASDAQ:ADXS) and Rani Therapeutics (NASDAQ:RANI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, media sentiment, valuation, earnings, profitability and institutional ownership.

Rani Therapeutics has a consensus price target of $8.75, indicating a potential upside of 889.37%. Given Rani Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Rani Therapeutics is more favorable than Ayala Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

7.2% of Ayala Pharmaceuticals shares are held by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are held by institutional investors. 0.6% of Ayala Pharmaceuticals shares are held by insiders. Comparatively, 26.7% of Rani Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Ayala Pharmaceuticals has a beta of 1.75, indicating that its share price is 75% more volatile than the broader market. Comparatively, Rani Therapeutics has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market.

Ayala Pharmaceuticals' return on equity of 0.00% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ayala Pharmaceuticals	N/A	N/A	N/A
Rani Therapeutics	N/A	-206.46%	-83.95%

In the previous week, Rani Therapeutics had 4 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 5 mentions for Rani Therapeutics and 1 mentions for Ayala Pharmaceuticals. Rani Therapeutics' average media sentiment score of 0.27 beat Ayala Pharmaceuticals' score of 0.00 indicating that Rani Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ayala Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rani Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Rani Therapeutics has lower revenue, but higher earnings than Ayala Pharmaceuticals. Rani Therapeutics is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A
Rani Therapeutics	$1.63M	67.11	-$29.67M	-$0.41	N/A

Summary

Rani Therapeutics beats Ayala Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Ayala Pharmaceuticals compare to Aardvark Therapeutics?

Ayala Pharmaceuticals (NASDAQ:ADXS) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations.

In the previous week, Aardvark Therapeutics had 11 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 12 mentions for Aardvark Therapeutics and 1 mentions for Ayala Pharmaceuticals. Ayala Pharmaceuticals' average media sentiment score of 0.00 beat Aardvark Therapeutics' score of -0.07 indicating that Ayala Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ayala Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aardvark Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ayala Pharmaceuticals' return on equity of 0.00% beat Aardvark Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ayala Pharmaceuticals	N/A	N/A	N/A
Aardvark Therapeutics	N/A	-61.71%	-56.29%

Ayala Pharmaceuticals has a beta of 1.75, suggesting that its share price is 75% more volatile than the broader market. Comparatively, Aardvark Therapeutics has a beta of 5.11, suggesting that its share price is 411% more volatile than the broader market.

Aardvark Therapeutics has a consensus price target of $19.70, indicating a potential upside of 350.80%. Given Aardvark Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aardvark Therapeutics is more favorable than Ayala Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.46

7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. 0.6% of Ayala Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Ayala Pharmaceuticals has higher revenue and earnings than Aardvark Therapeutics. Aardvark Therapeutics is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A

Summary

Ayala Pharmaceuticals beats Aardvark Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Ayala Pharmaceuticals compare to Genelux?

Genelux (NASDAQ:GNLX) and Ayala Pharmaceuticals (NASDAQ:ADXS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.

Genelux has higher earnings, but lower revenue than Ayala Pharmaceuticals. Genelux is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genelux	$10K	12,555.20	-$32.15M	-$0.85	N/A
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A

Genelux has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market. Comparatively, Ayala Pharmaceuticals has a beta of 1.75, suggesting that its stock price is 75% more volatile than the broader market.

In the previous week, Ayala Pharmaceuticals had 1 more articles in the media than Genelux. MarketBeat recorded 1 mentions for Ayala Pharmaceuticals and 0 mentions for Genelux. Ayala Pharmaceuticals' average media sentiment score of 0.00 beat Genelux's score of -0.45 indicating that Ayala Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Genelux	Neutral
Ayala Pharmaceuticals	Neutral

Genelux currently has a consensus target price of $18.00, indicating a potential upside of 542.86%. Given Genelux's stronger consensus rating and higher possible upside, equities analysts clearly believe Genelux is more favorable than Ayala Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Ayala Pharmaceuticals' return on equity of 0.00% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genelux	N/A	-174.55%	-123.65%
Ayala Pharmaceuticals	N/A	N/A	N/A

37.3% of Genelux shares are held by institutional investors. Comparatively, 7.2% of Ayala Pharmaceuticals shares are held by institutional investors. 7.5% of Genelux shares are held by insiders. Comparatively, 0.6% of Ayala Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Genelux beats Ayala Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Ayala Pharmaceuticals compare to Innate Pharma?

Innate Pharma (NASDAQ:IPHA) and Ayala Pharmaceuticals (NASDAQ:ADXS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings.

In the previous week, Innate Pharma had 1 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 2 mentions for Innate Pharma and 1 mentions for Ayala Pharmaceuticals. Innate Pharma's average media sentiment score of 0.26 beat Ayala Pharmaceuticals' score of 0.00 indicating that Innate Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innate Pharma	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ayala Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

0.2% of Innate Pharma shares are held by institutional investors. Comparatively, 7.2% of Ayala Pharmaceuticals shares are held by institutional investors. 31.9% of Innate Pharma shares are held by insiders. Comparatively, 0.6% of Ayala Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
Innate Pharma	N/A	N/A	N/A
Ayala Pharmaceuticals	N/A	N/A	N/A

Innate Pharma has a beta of 0.22, meaning that its stock price is 78% less volatile than the broader market. Comparatively, Ayala Pharmaceuticals has a beta of 1.75, meaning that its stock price is 75% more volatile than the broader market.

Innate Pharma presently has a consensus price target of $5.00, suggesting a potential upside of 146.31%. Given Innate Pharma's stronger consensus rating and higher probable upside, equities research analysts clearly believe Innate Pharma is more favorable than Ayala Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innate Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Ayala Pharmaceuticals has lower revenue, but higher earnings than Innate Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innate Pharma	$10.19M	18.71	-$55.64M	N/A	N/A
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A

Summary

Innate Pharma beats Ayala Pharmaceuticals on 9 of the 12 factors compared between the two stocks.

Get Ayala Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADXS vs. The Competition

Export

Metric	Ayala Pharmaceuticals	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$35.79M	$756.00M	$6.25B	$12.23B
Dividend Yield	N/A	4.84%	2.80%	5.32%
P/E Ratio	-0.08	1.49	20.79	25.05
Price / Sales	11.05	115.23	536.87	72.66
Price / Cash	N/A	20.07	43.09	54.25
Price / Book	-0.29	7.93	9.79	6.83
Net Income	-$48.07M	-$3.49M	$3.55B	$335.69M
7 Day Performance	N/A	-2.45%	-2.13%	-2.15%
1 Month Performance	N/A	67.60%	-4.16%	-2.47%
1 Year Performance	N/A	123.66%	28.31%	27.13%

Ayala Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADXS Ayala Pharmaceuticals	N/A	$0.60 flat	N/A	N/A	$35.79M	$3.24M	N/A	20
DERM Journey Medical	2.2281 of 5 stars	$5.16 +3.0%	$13.00 +151.9%	-8.9%	$136.93M	$61.86M	N/A	90	Earnings Report Analyst Revision High Trading Volume
RANI Rani Therapeutics	2.9551 of 5 stars	$1.05 -4.5%	$7.80 +642.9%	+26.3%	$136.06M	$1.63M	N/A	110	Earnings Report Analyst Upgrade
AARD Aardvark Therapeutics	2.7427 of 5 stars	$6.59 +7.9%	$22.60 +242.9%	-58.1%	$133.30M	N/A	N/A	18
GNLX Genelux	1.9683 of 5 stars	$3.19 +7.4%	$18.00 +464.3%	+7.3%	$133.18M	$10K	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ADXS) was last updated on 5/20/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ayala Pharmaceuticals (ADXS) Competitors

ADXS vs. DERM, RANI, AARD, GNLX, and IPHA

How does Ayala Pharmaceuticals compare to Journey Medical?

Summary

How does Ayala Pharmaceuticals compare to Rani Therapeutics?

Summary

How does Ayala Pharmaceuticals compare to Aardvark Therapeutics?

Summary

How does Ayala Pharmaceuticals compare to Genelux?

Summary

How does Ayala Pharmaceuticals compare to Innate Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADXS vs. The Competition

Ayala Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ayala Pharmaceuticals (ADXS) Competitors

ADXS vs. DERM, RANI, AARD, GNLX, and IPHA

How does Ayala Pharmaceuticals compare to Journey Medical?

Is ADXS or DERM more profitable?

Do institutionals and insiders have more ownership in ADXS or DERM?

Does the media refer more to ADXS or DERM?

Which has more risk and volatility, ADXS or DERM?

Do analysts recommend ADXS or DERM?

Which has preferable earnings & valuation, ADXS or DERM?

Summary

How does Ayala Pharmaceuticals compare to Rani Therapeutics?

Do analysts recommend ADXS or RANI?

Do insiders & institutionals have more ownership in ADXS or RANI?

Which has more risk and volatility, ADXS or RANI?

Is ADXS or RANI more profitable?

Does the media prefer ADXS or RANI?

Which has higher earnings and valuation, ADXS or RANI?

Summary

How does Ayala Pharmaceuticals compare to Aardvark Therapeutics?

Does the media prefer ADXS or AARD?

Is ADXS or AARD more profitable?

Which has more volatility and risk, ADXS or AARD?

Do analysts rate ADXS or AARD?

Do institutionals & insiders believe in ADXS or AARD?

Which has preferable earnings and valuation, ADXS or AARD?

Summary

How does Ayala Pharmaceuticals compare to Genelux?

Which has preferable valuation and earnings, GNLX or ADXS?

Which has more volatility & risk, GNLX or ADXS?

Does the media favor GNLX or ADXS?

Do analysts prefer GNLX or ADXS?

Is GNLX or ADXS more profitable?

Do institutionals & insiders have more ownership in GNLX or ADXS?

Summary

How does Ayala Pharmaceuticals compare to Innate Pharma?

Does the media prefer IPHA or ADXS?

Do insiders & institutionals hold more shares of IPHA or ADXS?

Is IPHA or ADXS more profitable?

Which has more risk & volatility, IPHA or ADXS?

Do analysts prefer IPHA or ADXS?

Which has stronger earnings & valuation, IPHA or ADXS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADXS vs. The Competition

Ayala Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools